Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > He Talks

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Nov 26, 2021 11:14am

132 Views

Post# 34168994

RE:He Talks

sell $1.5 million buy $100 grand back and say market is wrong

Duster340 wrote: about how the market has got it wrong, but yet does not make a statement and buy stock of any significance to put an end to the slide. to me it is just blah, blah, blah investors have tuned himout, he has lost the room. i may pick up some cheap stock when it reaches 50 cents

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth